Dec. 19, 2024—BD and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor’s offices, and other ambulatory care settings. The blood testing process integrates BD’s MiniDraw capillary blood collection system with Babson’s BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient’s finger. Samples can be collected and prepared by any trained health care worker, including those without prior phlebotomy experience.
“In areas of the U.S. where there are gaps in services or shortages of trained phlebotomy professionals, patients may experience delays in blood draws or not receive care they need,” Bridget Bagnato, worldwide president of specimen management at BD, said in a press statement. “By simplifying one of the most common procedures, together we’re making blood testing less invasive and more convenient to help health care organizations increase efficiency and access while helping to improving patient satisfaction and outcomes.”
The commercial partnership is an expansion of BD and Babson’s collaboration to advance capillary blood testing, which started in 2016 and has since evolved into a strategic partnership.